New Phase III analysis demonstrates Novartis Beovu showed improvement in best-corrected visual acuity in wet AMD patients with early persistent fluid
Oct 05, 2020
- In a post-hoc analysis?of HAWK and HARRIER, fewer?Beovu?(brolucizumab)?patients had early persistent fluid (12.5% vs. 20.4% of aflibercept patients), defined as the presence of intra-retinal fluid?and/or sub-retinal fluid through week 12 of treatment1
- Patients with early persistent fluid treated with?Beovu?experienced greater gains in best-corrected visual acuity (BCVA) at week 96 versus?patients?treated with aflibercept (6.4 vs.?3.7 letters, respectively)1
- This?data, along with?nine additional analyses of?HAWK and HARRIER?presented at EURETINA 2020 virtual congress,?further?support?Beovu?as an efficacious treatment option for wet AMD
- Lally D. An assessment of BCVA and CST outcomes with brolucizumab and aflibercept in patients with early persistent retinal fluid: 96 week pooled data from HAWK and HARRIER. Presented at: EURETINA 2020 congress. October 2020.
- Singh RP, et al. Multi-State Model Analysis of Central Subfield Thickness with Brolucizumab and Aflibercept in Neovascular Age-related Macular Degeneration: 96 week pooled data from HAWK and HARRIER. Presented at: EURETINA 2020 Congress. October 2020.
- Dugel P, Koh A, Ogura Y, et al; HAWK and HARRIER Study Investigators. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration.?J Ophthalmol. 2020;127(1):72-84
- Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: 96-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration [published online ahead of print].?J Ophthalmol. 2020. https://doi.org/10.1016/j.ophtha.2020.06.028.
- Nimz EL, et al. Intraocular and systemic pharmacokinetics of brolucizumab (RTH258) in nonhuman primates. Presented at: Association for Research in Vision and Ophthalmology (ARVO) annual meeting. 2016. Abstract 4996
- Escher D, et al. Single-chain antibody fragments in ophthalmology. Presented at: EURETINA congress. 2015. Abstract.
- Gaudreault J, et al. Preclinical pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration.?Invest Ophthalmol Vis Sci?2012;53:3025.
- Tietz J, et al. Affinity and Potency of RTH258 (ESBA1008), a Novel Inhibitor of Vascular Endothelial Growth Factor A for the Treatment of Retinal Disorders.?IOVS. 2015; 56(7):1501.
- Kim R. Introduction, mechanism of action and rationale for anti-vascular endothelial growth factor drugs in age-related macular degeneration.?Indian J Ophthalmol. 2007;55(6):413-415.
- Beovu [US prescribing information] East Hanover, NJ. Novartis: 2019.
- Beovu [summary of product characteristics] Basel, Switzerland. Novartis: 2020.
- Pharma Japan. National Health Insurance Pricing. Available at:?https://pj.jiho.jp/sites/default/files/pj/document/2020/05/New%20Drugs%20to%20Be%20Added%20to%20NHI%20Price%20List%20on%20May%2020_1.pdf. Accessed September 2020.
- Canadian Agency for Drugs and Technologies in Health. CADTH Canadian Drug Expert Committee Recommendation. Available at:?https://cadth.ca/sites/default/files/cdr/complete/SR0632%20Beovu%20-%20CDEC%20Final%20Recommendation%20%E2%80%93%20May%2025%2C%202020_for%20posting.pdf. Accessed September 2020.
- Beovu [prescription medicine decision summary] Australia. Novartis: 2020.
# # #
Novartis Media Relations E-mail:?media.relations@novartis.comPeter Zuest Novartis External Communications + 41 79 899 9812 (mobile) peter.zuest@novartis.com Eric Althoff Novartis US External Communications +1 646 438 4335 eric.althoff@novartis.com | Amy Wolf Novartis Division Communications + 41 61 696 58 94 (direct) + 41 79 576 07 23 (mobile) amy.wolf@novartis.com |
Central | North America | ||
Samir Shah | +41 61 324 7944 | Sloan Simpson | +1 862 778 5052 |
Thomas Hungerbuehler Isabella Zinck | +41 61 324 8425 +41 61 324 7188 |